These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25472026)

  • 21. Predictive value of Ki67 for adjuvant chemotherapy in node-negative, hormone receptor-positive breast cancer.
    Sutepvarnon A; Warnnissorn M; Srimuninnimit V
    J Med Assoc Thai; 2013 Feb; 96 Suppl 2():S60-6. PubMed ID: 23590023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy.
    Wong H; Lau S; Cheung P; Wong TT; Parker A; Yau T; Epstein RJ
    BMC Cancer; 2014 Nov; 14():826. PubMed ID: 25385074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
    Kneubil MC; Brollo J; Botteri E; Curigliano G; Rotmensz N; Goldhirsch A; Lohsiriwat V; Manconi A; Martella S; Santillo B; Petit JY; Rietjens M
    Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Factors for Luminal B-like Breast Cancer.
    Ding NH; Liu CF; Hu C; Yuan JQ; Liao WH; Xiao Z
    Curr Med Sci; 2019 Jun; 39(3):396-402. PubMed ID: 31209809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
    J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients.
    Haroon S; Hashmi AA; Khurshid A; Kanpurwala MA; Mujtuba S; Malik B; Faridi N
    Asian Pac J Cancer Prev; 2013; 14(7):4353-8. PubMed ID: 23992002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
    Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
    Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incorporating progesterone receptor expression into the PREDICT breast prognostic model.
    Grootes I; Keeman R; Blows FM; Milne RL; Giles GG; Swerdlow AJ; Fasching PA; Abubakar M; Andrulis IL; Anton-Culver H; Beckmann MW; Blomqvist C; Bojesen SE; Bolla MK; Bonanni B; Briceno I; Burwinkel B; Camp NJ; Castelao JE; Choi JY; Clarke CL; Couch FJ; Cox A; Cross SS; Czene K; Devilee P; Dörk T; Dunning AM; Dwek M; Easton DF; Eccles DM; Eriksson M; Ernst K; Evans DG; Figueroa JD; Fink V; Floris G; Fox S; Gabrielson M; Gago-Dominguez M; García-Sáenz JA; González-Neira A; Haeberle L; Haiman CA; Hall P; Hamann U; Harkness EF; Hartman M; Hein A; Hooning MJ; Hou MF; Howell SJ; ; ; Ito H; Jakubowska A; Janni W; John EM; Jung A; Kang D; Kristensen VN; Kwong A; Lambrechts D; Li J; Lubiński J; Manoochehri M; Margolin S; Matsuo K; Taib NAM; Mulligan AM; Nevanlinna H; Newman WG; Offit K; Osorio A; Park SK; Park-Simon TW; Patel AV; Presneau N; Pylkäs K; Rack B; Radice P; Rennert G; Romero A; Saloustros E; Sawyer EJ; Schneeweiss A; Schochter F; Schoemaker MJ; Shen CY; Shibli R; Sinn P; Tapper WJ; Tawfiq E; Teo SH; Teras LR; Torres D; Vachon CM; van Deurzen CHM; Wendt C; Williams JA; Winqvist R; Elwood M; Schmidt MK; García-Closas M; Pharoah PDP
    Eur J Cancer; 2022 Sep; 173():178-193. PubMed ID: 35933885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Higher Ki67 expression is associates with unfavorable prognostic factors and shorter survival in breast cancer.
    Kilickap S; Kaya Y; Yucel B; Tuncer E; Babacan NA; Elagoz S
    Asian Pac J Cancer Prev; 2014; 15(3):1381-5. PubMed ID: 24606469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulatory effect of neoadjuvant chemotherapy on the prognosis of patients with breast cancer.
    Trifunovic J; Memisevic N; Nikolin B; Salma S; Dugandzija T; Vidovic V
    J BUON; 2017; 22(2):638-643. PubMed ID: 28730768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.
    Khande TA; Joshi AR; Khandeparkar SGS; Kulkarni MM; Gogate BP; Kakade AR; Sahu PD; Khillare CD
    Indian J Cancer; 2020; 57(2):190-197. PubMed ID: 32445323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prognostic factors of breast cancer].
    Tang P; Wei B; Yang WJ; Liu YS; Bu H
    Zhonghua Bing Li Xue Za Zhi; 2011 Feb; 40(2):73-6. PubMed ID: 21426799
    [No Abstract]   [Full Text] [Related]  

  • 35. Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis.
    Van Belle V; Van Calster B; Brouckaert O; Vanden Bempt I; Pintens S; Harvey V; Murray P; Naume B; Wiedswang G; Paridaens R; Moerman P; Amant F; Leunen K; Smeets A; Drijkoningen M; Wildiers H; Christiaens MR; Vergote I; Van Huffel S; Neven P
    J Clin Oncol; 2010 Sep; 28(27):4129-34. PubMed ID: 20713855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
    Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
    Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
    Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
    Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
    Cuzick J; Dowsett M; Pineda S; Wale C; Salter J; Quinn E; Zabaglo L; Mallon E; Green AR; Ellis IO; Howell A; Buzdar AU; Forbes JF
    J Clin Oncol; 2011 Nov; 29(32):4273-8. PubMed ID: 21990413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.